Saliou P, Stoeckel P, Lafaye A, Rey J L, Renaudet J
Dev Biol Stand. 1978;41:97-108.
After the first tests of this vaccine in Egypt (1972) and in the Sudan (1973), two controlled tests in the field were performed in two high-risk areas for meningitis: --firstly, in the region of Koudougou (Upper-Volta), in November-December 1973 (17,300 vaccines). Its major aim was to solve operational and logistical problems; --secondly, in the Koutiala (Mali) area, according to a very strict schedule, in November-December 1975 and December 1975 (37,979 vaccines). The complete innocuousness of the vaccine was proven and excellent seroconversion was observed after its administration. On the individual level, it was confirmed that the vaccine ensures excellent protection for a period of at least three years. This new prophylactic weapon inspires the authors to suggest a new strategy in the fight against meningitis epidemics caused by meningococcus in the African Sahel area, taking into account the current increase there in serogroup C, against which there is also a vaccine whose efficacy has already been demonstrated.
1972年在埃及和1973年在苏丹对这种疫苗进行首次测试后,在脑膜炎两个高风险地区进行了两项现场对照试验:——首先,1973年11月至12月在库杜古(上沃尔特)地区(17300剂疫苗)。其主要目的是解决操作和后勤问题;——其次,1975年11月至12月以及1975年12月,在库蒂亚拉(马里)地区按照非常严格的时间表(37979剂疫苗)。疫苗的完全无害性得到证实,接种后观察到良好的血清转化。在个体层面,证实该疫苗至少能提供三年的良好保护。这种新的预防武器促使作者们考虑到目前非洲萨赫勒地区C群血清型增加的情况,建议在抗击由脑膜炎球菌引起的脑膜炎流行方面采取新战略,针对C群也有一种已证明有效的疫苗。